Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP: panitumumab + pemetrexed/cisplatin versus pemetrexed/cisplatin in first-line nonsquamous NSCLC
2009-014677-41Phase 2Terminated
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
- Start
- Nov 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Panitumumab + pemetrexed + cisplatin with Pemetrexed + cisplatin (2 arms). Primary endpoint: Progression-free survival rate at 6 months. Started Nov 2009; status: terminated.
02
Drugs
panitumumabpemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-014677-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014677-41.